Trial Profile
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs CEP 9722 (Primary)
- Indications Breast cancer; Gastric cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Cephalon; Teva Pharmaceutical Industries
- 18 Aug 2023 Interventional Study Model changed to Sequential, number of treatment arms changed to 7.
- 18 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.